Navigation Links
China Nepstar Chain Drugstore Announces New Management Team Members
Date:1/5/2009

SHENZHEN, China, Jan. 5 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or "the Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced the appointment of Mr. Ian Wade, a retail industry veteran with an outstanding track record of success, as the Co-Chief Executive Officer. Concurrently, the Company announced the appointment of Mr. William Weili Dai as the new Chief Financial Officer. Both appointments will be effective on January 5, 2009.

Formally with AS Watson as the Group Managing Director for 25 years, Mr. Ian Wade managed one of the world's largest and fastest growing global retail companies, with over 7,700 stores in 37 countries. During his tenure at AS Watson, he turned the Hong Kong based business, which then had 16 stores, into a highly profitable, international retail chain with extensive reach throughout Asia and Europe. Under his leadership, Watson opened 270 stores in mainland China and 400 stores in Taiwan, and launched groundbreaking hypermarkets in mainland China. In addition, Mr. Wade also managed Watson's retail operations and private label businesses in many countries in Europe.

Mr. William Weili Dai brings to Nepstar over 15 years of experience in financial management and accounting. Prior to joining Nepstar, Mr. Dai was the chief financial officer of MicroPort Medical, a leading medical device company in China. From 1996 to 2006, Mr. Dai served as finance manager in charge of China operations for three leading global companies, Mundipharma Pharmaceuticals, Boston Scientific and Case Corporation. During his tenure at Mundipharma and Boston Scientific, he was involved in multiple strategic M&A and business development projects in China. Mr. Dai began his financial management career with Ford Motor Company in Michigan in 1993 as financial analyst and later became the component department controller and then the assistant to the CFO of Ford's joint venture in China. Mr. Dai received his MBA from Michigan State University and his BA from Shanghai University.

"We are excited to welcome Mr. Wade and Mr. Dai to our management team. With their breadth of experience, we are confident that they will be valuable contributors to Nepstar," commented Mr. Simin Zhang, Chairman of China Nepstar.

Mr. Jiannong Qian, Co-Chief Executive Officer, will continue to focus on new business development, acquisitions and partnership development, while Mr. Wade will focus on maximizing operating efficiencies and profitable growth. Upon the appointment of Mr. Dai, Mr. Zixin Shao, the interim Chief Financial Officer, will resume his role as financial controller.

About China Nepstar Chain Drugstore Ltd.

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain based on the number of directly operated stores. As of September 30, 2008, the Company had 2,667 stores across 76 cities, one headquarters distribution center and 11 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the robust economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For more information, please contact:

    In China:
     Lucia Qian
     China Nepstar Chain Drugstore Ltd.
     Marketing and IR Director
     Phone: +86-755-2641-4065
     Email: qianrt@nepstar.cn

    In the United States:
     Dixon Chen
     Grayling Global
     Investor Relations
     Tel:   +1-646-284-9403
     Email: dchen@hfgcg.com

     Ivette Almeida
     Grayling Global
     Media Relations
     Tel:   +1-646-284-9455
     Email: ialmeida@hfgcg.com

'/>"/>
SOURCE China Nepstar Chain Drugstore Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Nepstar Chain Drugstore Terminates Voting Rights Agreement for Yunnan Subsidiary
2. China Medical Technologies Announces the Completion of the Sale of its HIFU Business
3. Is Echinacea In or Out? Should You Stock Up on Zinc? Whys the Neti Pot So Hot?
4. China Biopharma, Inc. Issues Corporate Information Update
5. Watching water from space could aid disease prevention in China
6. China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs
7. Chinas Views on Mental Disorders Improving but Challenges Remain
8. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
9. China Shenghuo to Resume Trading on NYSE Alternext US LLC
10. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
11. China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... a pilot study of ActiGraph’s CentrePoint Data Hub in a sample ... provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Healthcare companies are ... they will rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare ... your executive resume and wondering if it’s as ready as you are for a ...
(Date:4/27/2017)... ... April 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion ... this year. , The first new location will open at the corner of ... 84th and Northern Lights Drive this fall. And the third location is in the ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 24, 2017 Solentim, the developer of ... addition of a major new product line called ... The VIPS has been developed for automatically seeding ... as part of the process to generate clonally-derived ... and more reliable solution when compared to traditional ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
Breaking Medicine Technology: